



- (51) **International Patent Classification:**
C07D 401/06 (2006.01) *A61P 3/04* (2006.01)
A61K 31/454 (2006.01)
- (21) **International Application Number:**
PCT/US2013/037159
- (22) **International Filing Date:**
18 April 2013 (18.04.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/636,108 20 April 2012 (20.04.2012) US
- (71) **Applicants:** **HELSINN HEALTHCARE SA** [CH/CH];
Via Pian Scairolo 9, Pazzallo Lugano, 6912 (CH). **ONO
PHARMACEUTICAL CO., LTD.** [JP/JP]; 1-5,
Doshomachi 2-chome, Chuo-ku, Osaka, 5418526 (JP).
- (72) **Inventors:** **KUWABE, Shin-itsu**; 1-5, Doshomachi 2-
chome, Chuo-ku, Osaka, 5418526 (JP). **YANAGIMA-
CHI, Takehiko**; 1-5, Doshomachi 2-chome, Chuo-ku,
Osaka, 5418526 (JP). **YOSHIYAMA, Hideyuki**; 1-5,
Doshomachi 2-chome, Chuo-ku, Osaka, 5418526 (JP).
- (72) **Inventor:** **PINES, Seemon** (*deceased*).
- (72) **Inventors:** **DE GROOT, Eleanor**; 3722 Sunset Blvd.,
Houston, TX 77005 (US). **GARCIA RUBIO, Silvina**; 7
Bellflower Ct., Princeton, NJ 08540 (US). **MANINI,
Peter**; Via Dr. Falleroni 2, 6512 Giubiasco (CH).

- (74) **Agent:** **SULLIVAN, Clark G.**; Arnall Golden Gregory
LLP, 171 17th Street, NW, Suite 2100, Atlanta, GA 30363
(US).

- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** METHODS OF PRODUCING ANAMORELIN HYDROCHLORIDE HAVING CONTROLLED CHLORIDE CON-
TENT

(57) **Abstract:** The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising
anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state,
processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.

